Peripheral artery disease (PAD) is a major health problem with increased cardiovascular
mortality, morbidity and disabling critical limb threatening ischemia (CLTI) and amputation …

Peripheral arterial disease (PAD) is a highly prevalent atherosclerotic condition. In patients
with PAD, the presence of intermittent claudication leads to a deterioration in quality of life. In …

Aims In this secondary analysis of the VOYAGER trial, rivaroxaban 2.5 mg twice/day plus
aspirin 100 mg/day was assessed in older adults. Advanced age is associated with elevated …

Objective Peripheral arterial disease (PAD) trends remain unclear because contemporary
data are sparse and conflicting. This nationwide cohort study quantified changes in PAD …

About 230 million people worldwide suffer from peripheral arterial disease (PAD), and the
prevalence is increasing year by year. Multiple risk factors, including smoking, dyslipidemia …

Objective In the VOYAGER PAD trial, rivaroxaban 2.5 mg plus aspirin significantly reduced
the primary composite efficacy outcome of acute limb ischaemia, major amputation …

Objective The VOYAGER-PAD trial demonstrated the interest in dual pathway inhibition
(DPI)(low dose rivaroxaban plus aspirin) to reduce limb and cardiovascular events after …

Objective The OAC 3-PAD score was developed to predict bleeding risk in patients with
lower extremity peripheral arterial disease (PAD), but its performance in concomitant …

Objective Adherence to antiplatelet therapy is recommended but unexplored in patients with
symptomatic lower extremity peripheral arterial disease (PAD). Therefore, this study aimed …

Peripheral artery disease (PAD) is a major cause of morbidity and mortality but it is usually
underdiagnosed and undertreated. Patients with PAD present dysregulated procoagulant …